Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis

Multiple myeloma (MM) is the second most frequent hematologic cancer in the United States. Carfilzomib (CFZ), an irreversible proteasome inhibitor being used to treat relapsed and refractory MM, has been associated with cardiotoxicity, including heart failure. We hypothesized that a multi-omics appr...

Descripción completa

Detalles Bibliográficos

Autores principales:	Marwa Tantawy, Lakshmi Manasa Chekka, Yimei Huang, Timothy J. Garrett, Sonal Singh, Chintan P. Shah, Robert F. Cornell, Rachid C. Baz, Michael G. Fradley, Nida Waheed, David L. DeRemer, Lihui Yuan, Taimour Langaee, Keith March, Carl J. Pepine, Jan S. Moreb, Yan Gong
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2021-04-01
Colección:	Frontiers in Cardiovascular Medicine
Materias:	proteasome inhibitors Cardio-oncology carfilzomib metabolomcis proteomic
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fcvm.2021.645122/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!